Why Independent Pharmacies Are Closing

The 2,275 figure is from the NCPA 2024 State of the Independent Pharmacy report, tracking net closures (closures minus openings) among US independently-owned community pharmacies. It represents a 4.3% attrition rate against the ~21,500 independents operating at the start of 2024.

The trend is accelerating. NCPA data shows: 2020 closures = 1,231, 2021 = 1,489, 2022 = 1,712, 2023 = 1,946, 2024 = 2,275. A 15-18% year-over-year acceleration.

By comparison, chain pharmacy closures over the same period have been more visible (CVS closing 900 stores 2022-24, Walgreens closing 1,200+, Rite Aid bankruptcy) but represent a smaller percentage of the chain footprint.

1. PBM DIR fee clawbacks. In 2024 alone, independents paid an estimated $12.6B in DIR fees to PBMs. A typical 200-Rx/day pharmacy loses $150K-200K per year to DIR reconciliation. Try our DIR Fee Calculator to see your specific exposure.

2. Below-cost reimbursement on generics. MAC (Maximum Allowable Cost) pricing has fallen faster than wholesale acquisition cost on many high-volume generics. NCPA data shows the median independent pharmacy loses money on ~15% of Medicaid fills and ~8% of Medicare Part D fills.

3. Amazon Pharmacy + mail-order shift. Amazon Pharmacy quietly captured 4-6% of US retail prescription market share by 2025 (JP Morgan estimate). Amazon's $5 flat-price generic tier undercuts most independent cash prices.

4. Wholesale inflation. Cardinal Health, McKesson, and AmerisourceBergen have raised distribution fees 8-12% since 2022 while reimbursement growth has been flat. Independent pharmacies without PSAO leverage take the biggest hit.

Cash-pay diversification. Pharmacies that generate 15-25% of revenue from cash-pay patients are 3.2× more likely to be profitable than pure PBM-dependent pharmacies (NCPA 2024 profitability study). Cash-pay revenue has zero DIR exposure, no MAC squeeze, no PBM clawback risk.

Specialty niche expansion. 503A compounding, veterinary compounding, hormone replacement therapy, and weight-loss injectables (semaglutide, tirzepatide) generate 40-60% margins compared to 8-12% on standard retail. Pharmacies with a compounding niche are closing at half the rate of general independents.

PSAO membership + collective bargaining. Independent pharmacies in a PSAO (AmerisourceBergen Elevate, Cardinal LEADER, McKesson Health Mart Atlas) pay ~20% less in DIR fees on average and get 8-15% better wholesale contracts.

Adherence programs + star rating optimisation. Pharmacies at 4-5 stars pay 30-50% less DIR than 2-3 star pharmacies. Med-sync + blister packaging is the highest-leverage improvement.